Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Robert Rose who wrote (2864)	2/9/2001 5:23:42 PM
From: Jibacoa	Read Replies (2) \| Respond to of 52153

I should probably ask Peter to excuse me for mentioning this stock, although it is not really a "penny" stock since last year H was around $7 (Canadian) and it presently trades around $3.80 (C) At any rate, what picked my curiosity was all those reports coming about the "simple tests" that the company seems to have. Back at the Am. Heart Assoc. meeting in New Orleans last Nov., Dr.Dennis Specher from the Cleveland Clinic, presented the results of the spectrometry test for cholesterol. He evaluated the test on 381 patients scheduled to undergo coronary angiography. The test is not invasive and measures the amount of cholesterol that adheres to the skin, which in turn is supposed to correlate to the levels on the coronary endothelial cells.According to the results there was better correlation with coronary lesions and the test than with blood cholesterol levels. The test called Cholesterol 1,2,3 (since it takes 3 minutes to run) is also been evaluated at the Department of Medicine of University of British Columbia and it received a license from the TTP at Health Canada on Jan.29 (That news halted trading on the stock at Toronto exchange for a couple of hours).It is the first non-invasive test for cholesterol that has been approved in Canada. The company is reportedly working on a lung cancer screening test, which is also non-invasive and tries to measure with a hand held spectrophotometer levels of a cancer marker in sputum.Those tests are being conducted at St.Joseph's Hosp.-McMaster Univ. in Hamilton, Ontario.The results of that test called LungAlert are supposed to be presented at the annual meeting of the Am.Thoracic Soc. in San Francisco on May 21. The company is also working on a colorectal cancer screening test called ColorectAlert and a urine based prostate cancer test. All of which sounded interesting, although I have seen some companies with so called "cancer screening tests" which have had rather disappointed results, to say the least.<g> Bernard